Lipe & Dalton Vertex Pharmaceuticals Inc Transaction History

Lipe & Dalton

$186 Million
Q2 2024

A detailed history of Lipe & Dalton transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lipe & Dalton holds 5,041 shares of VRTX stock, worth $2.39 Million. This represents 1.27% of its overall portfolio holdings.

Number of Shares

5,041

Previous 5,135 1.83%

Holding current value

$2.39 Million

Previous $2.15 Million 10.11%

% of portfolio

1.27%

Previous 1.11%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	SELL	$392.81 - $485.53 $36,924 - $45,639	-94 Reduced 1.83%	5,041 $2.36 Million
Q4 2023 Jan 30, 2024	BUY	$343.0 - $410.68 $34,300 - $41,068	100 Added 1.99%	5,135 $2.09 Million
Q2 2023 Jul 26, 2023	SELL	$314.42 - $351.91 $15,721 - $17,595	-50 Reduced 0.98%	5,035 $1.77 Million
Q1 2023 May 02, 2023	SELL	$283.23 - $323.1 $28,323 - $32,310	-100 Reduced 1.93%	5,085 $1.6 Million
Q4 2022 Feb 03, 2023	SELL	$285.76 - $321.48 $14,288 - $16,074	-50 Reduced 0.96%	5,185 $1.5 Million
Q3 2022 Nov 07, 2022	SELL	$273.83 - $305.53 $2,738 - $3,055	-10 Reduced 0.19%	5,235 $1.52 Million
Q2 2022 Aug 01, 2022	BUY	$234.96 - $292.55 $93,984 - $117,020	400 Added 8.26%	5,245 $1.48 Million
Q1 2022 Apr 26, 2022	BUY	$221.42 - $260.97 $143,923 - $169,630	650 Added 15.49%	4,845 $1.26 Million
Q3 2021 Nov 01, 2021	SELL	$181.39 - $202.99 $37,184 - $41,612	-205 Reduced 4.66%	4,195 $761,000
Q2 2021 Aug 02, 2021	BUY	$187.49 - $221.1 $45,935 - $54,169	245 Added 5.9%	4,400 $887,000
Q1 2021 Apr 30, 2021	SELL	$207.02 - $241.31 $46,579 - $54,294	-225 Reduced 5.14%	4,155 $893,000
Q4 2020 Jan 29, 2021	BUY	$207.01 - $276.09 $906,703 - $1.21 Million	4,380 New	4,380 $1.04 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lipe & Dalton, based on Form 13F filings with the SEC.

News

Stay updated on Lipe & Dalton with notifications on news.

Account